PPLPHARMA - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.2
| Stock Code | PPLPHARMA | Market Cap | 19,021 Cr. | Current Price | 143 ₹ | High / Low | 241 ₹ |
| Stock P/E | 25.8 | Book Value | 58.2 ₹ | Dividend Yield | 0.10 % | ROCE | 12.4 % |
| ROE | 9.74 % | Face Value | 10.0 ₹ | DMA 50 | 159 ₹ | DMA 200 | 181 ₹ |
| Chg in FII Hold | -0.61 % | Chg in DII Hold | 0.79 % | PAT Qtr | 151 Cr. | PAT Prev Qtr | 196 Cr. |
| RSI | 35.1 | MACD | -5.42 | Volume | 29,93,700 | Avg Vol 1Wk | 46,37,699 |
| Low price | 135 ₹ | High price | 241 ₹ | PEG Ratio | 1.16 | Debt to equity | 0.12 |
| 52w Index | 8.04 % | Qtr Profit Var | 27.4 % | EPS | 5.39 ₹ | Industry PE | 27.6 |
📊 Analysis: PPLPHARMA trades at ₹143, well below both 50 DMA (₹159) and 200 DMA (₹181), showing strong short-term weakness. RSI at 35.1 indicates oversold territory, but MACD negative (-5.42) confirms bearish momentum. Volume is below weekly average, reducing intraday conviction. Fundamentals are moderate with ROCE 12.4% and ROE 9.74%, but valuation is fair (P/E 25.8 vs industry 27.6). Intraday bias is bearish, with only limited recovery potential near support zones.
💡 Optimal Buy Price: ₹140–143 if price stabilizes near support.
🎯 Profit Exit Levels: ₹148 (first target), ₹152 (second target).
🛡️ Stop-Loss: ₹137 (below intraday support).
⏱️ If Already Holding: Exit near ₹148–152 if momentum weakens. If price breaks below ₹137 with volume spike, cut position immediately.
✅ Positive
- EPS at ₹5.39 shows earnings presence.
- DII holdings increased (+0.79%).
- PEG ratio at 1.16 indicates reasonable valuation relative to growth.
- Debt-to-equity ratio at 0.12, manageable leverage.
⚠️ Limitation
- Stock trades below both 50 DMA and 200 DMA.
- Weak momentum indicators (RSI 35.1, MACD -5.42).
- Volume below weekly average, reducing intraday conviction.
- Low ROCE (12.4%) and ROE (9.74%).
📉 Company Negative News
- Quarterly PAT declined from ₹196 Cr. to ₹151 Cr.
- FII holdings decreased (-0.61%).
📈 Company Positive News
- Quarterly profit variation shows +27.4% YoY improvement despite sequential dip.
- DII inflows (+0.79%) show domestic support.
🏭 Industry
- Industry P/E at 27.6, PPLPHARMA trades at 25.8, showing fair valuation.
- Pharma sector demand remains resilient, supported by healthcare spending.
🔎 Conclusion
PPLPHARMA is a high-risk intraday candidate. Momentum indicators suggest caution, with weak price action and declining profits. Best approach: buy only near ₹140–143 if support holds, exit at ₹148–152, and protect downside with stop-loss at ₹137.
Would you like me to extend this into a peer benchmarking overlay with other mid-cap pharma stocks (e.g., Alkem Labs, Torrent Pharma, Divi’s Labs) so you can see if PPLPHARMA is underperforming or showing relative strength intraday?